Vera Therapeutics (VERA) Corporate presentation summary

Company overview and financials

• Founded in San Francisco in 2016, led by an experienced development and commercialization team.

• Raised over $1.8B to date, including a recent $300M oversubscribed public financing.

• Strong financial position with ~$779M in cash and equivalents as of December 31, 2025, and $425M additional non-dilutive capital available.

• IPO on Nasdaq in May 2021; 71.3M shares outstanding.

Pipeline and product focus

• Pipeline includes atacicept (dual BAFF/APRIL inhibitor) for IgAN, pMN, FSGS, MCD, and other autoimmune indications.

• MAU868 for BK virus and VT-109 in research and discovery stages.

• Holds worldwide, exclusive rights to develop and commercialize atacicept, VT-109, and MAU868.

Atacicept mechanism and clinical data

• Atacicept is a rationally designed TACI-Fc fusion protein that binds BAFF and APRIL with high affinity, modulating B cells and autoantibodies.

• Demonstrated significant reduction in Gd-IgA1, proteinuria, and hematuria, with stabilization of eGFR in long-term Phase 2b and Phase 3 trials.

• Phase 3 ORIGIN 3 trial showed a 46% reduction in UPCR at 36 weeks versus 7% for placebo (p<0.0001), with efficacy consistent across subgroups.

• 67% reduction in Gd-IgA1 and 81% hematuria resolution at 36 weeks; rapid and sustained response observed.